- Actions of Management Board and Supervisory Board approved
- New Supervisory Board elected: Prof. Dr Wolfgang Plischke new Chairman of the Supervisory Board
- Authorised Capital 2014 created
HAMBURG, Germany, June 17, 2014 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt: EVT ) (TecDAX) (ISIN:DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting.
The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the Company's performance for the year 2013 and provided the shareholders with an update on the topic "Execute & Innovate 20 years of Research – 20 years of Evotec."
At the Annual General Meeting, the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2013 were approved. Furthermore, a new Supervisory Board was elected by the Annual General Meeting. The term of the new Supervisory Board ends with the close of the Annual General Meeting charged with approving the actions of the members of the Supervisory Board in the 2018 fiscal year. Prof. Dr Wolfgang Plischke, former member of the Management Board of Bayer AG, Prof. Dr Iris Löw-Friedrich, Chief Medical Officer and Executive Vice President of UCB S.A., and Prof. Dr Paul Linus Herrling, former global Head of Research of Novartis Pharma AG and Chairman of the Board of the Novartis Institute for Tropical Diseases joined the Supervisory Board as new members. Three former members of the Supervisory Board, Dr Walter Wenninger, Dr Claus Braestrup and Bernd Hirsch, were re-elected as members of the new Supervisory Board of Evotec.
In a subsequent meeting of the Supervisory Board, Prof. Dr Wolfgang Plischke was elected as Chairman of the Supervisory Board and Dr Walter Wenninger, former Chairman of the Supervisory Board of Evotec, was elected as his Vice Chairman.
"I'd like to express my sincere gratitude to the parting members of the Supervisory Board, Mary Tanner, Roland Oetker and Prof. Dr Andreas Pinkwart, also on behalf of my colleagues in the Management Board, for their constructive and successful collaboration over the last years," said Dr Werner Lanthaler, Chief Executive Officer of Evotec . "At the same time, I'd like to thank the remaining members of the Supervisory Board for their continued commitment and warmly welcome Prof. Dr Iris Löw-Friedrich, Prof. Dr Wolfgang Plischke and Prof. Dr Paul Linus Herrling to the Supervisory Board of Evotec AG."
The Annual General Meeting also approved the proposal of the Management Board and the Supervisory Board to create a new Authorised Capital 2014. Moreover, the Annual General Meeting passed the other agenda items requiring shareholders' approval, hereunder the resolution on single amendments of the Articles of Association and the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year 2014.
At the ordinary Annual General Meeting 2014 of Evotec AG, 34.9% of the voting capital was present.
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com .
FORWARD LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
For further information, please contact Gabriele Hansen VP, Corporate Communications & Investor Relations +49.(0)40.560 81-255 +49.(0)40.560 81-333 Fax Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg (Germany)
